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Abstract
Background: Carcinoma in situ (CIS) is believed to be a precursor of invasive bladder cancer.
Identification of CIS is a valuable prognostic factor since radical treatment strategies can be offered
these patients before the disease becomes invasive.
Methods: We developed a pathway based classifier approach to predict presence or absence of
CIS in patients suffering from non muscle invasive bladder cancer. From Ingenuity Pathway Analysis
we considered four canonical signalling pathways (p38 MAPK, FGF, Calcium, and cAMP pathways)
with most coherent expression of transcription factors (TFs) across samples in a set of twenty-
eight non muscle invasive bladder carcinomas. These pathways contained twelve TFs in total. We
used the expression of the TFs to predict presence or absence of CIS in a Leave-One-Out Cross
Validation classification.
Results: We showed that TF expression levels in three pathways (FGF, p38 MAPK, and calcium
signalling) or the expression of the twelve TFs together could be used to predict presence or
absence of concomitant CIS. A cluster analysis based on expression of the twelve TFs separated
the samples in two main clusters: one branch contained 11 of the 15 patients without concomitant
CIS and with the majority of the genes being down regulated; the other branch contained 10 of 13
patients with concomitant CIS, and here genes were mostly up regulated. The expression in the
CIS group was comparable to the expression of twenty-three patients suffering from muscle-
invasive bladder carcinoma. Finally, we validated our results in an independent test set and found
that prediction of CIS status was possible using TF expression of the p38 MAPK pathway.
Conclusion: We conclude that it is possible to use pathway analysis for molecular classification of
bladder tumors.
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Background
Carcinoma in situ (CIS) is characterized by flat, non-pap-
illary, disordered proliferation and differentiation of
urothelial cells. The tumor cells are per definition high
grade and are usually associated with significant architec-
tural disorder like loss of polarity and maturation [1]. The
cells are highly dysplastic and only weakly adherent.
Though CIS is a non-invasive condition progression to the
invasive stage is seen in about 50% of the cases [2].
It is believed that bladder tumors develop through at least
two distinct genetic pathways: A low grade form and a
high grade form often associated with concomitant CIS.
The low grade form is frequently associated with loss-of-
heterozygocity (LOH) in chromosome 9 and activating
mutation of the FGF receptor 3 (FGFR3). These tumors
often recur but seldom progress to an invasive stage. The
high grade form is characterised by TP53 gene inactivation
and progression to a muscle invasive stage seems to
require a subsequent loss of chromosome 9 [3]. CIS is
believed to be a precursor of muscle invasive cancers [3-5].
CIS is seldom diagnosed as the primary lesion, since CIS
is rarely occurring alone, and may be associated with few
symptoms. CIS is usually diagnosed from selected site
biopsies taken at cystoscopies, however, the procedure is
time-consuming and discomforting to the patients. There-
fore, the ability to diagnose CIS before the disease
progresses would be extremely valuable and important for
establishment of appropriate treatment. Efforts have been
made to make such diagnoses using expression profiling.
Dyrskjot et al. previously showed that tumors with sur-
rounding CIS have a notably different expression profile
than tumors without CIS [6,7] and they were able to con-
struct a 16-gene CIS classifier [6]. Using this gene signa-
ture derived from papillary non muscle invasive tumors
they could discriminate CIS lesions from normal urothe-
lium samples obtained from individuals with no bladder
cancer history. They therefore suggested that for bladder
tumors with concomitant CIS, a CIS signature is present in
general in the urothelium no matter whether the urothe-
lial cells are organized as tumors, as flat lesions, or as his-
tologically normal-appearing urothelium adjacent to
tumor lesions [6]. Furthermore, specific gene expression
patterns in tumors with concomitant CIS were found to
resemble the gene expression found in muscle invasive
tumors. [7]. These findings were confirmed by Wild [8].
The role of FGFR3 mutations in bladder cancer has been
intensively studied in the last decade and it has been
shown that activating mutations of FGFR3 is related to
tumors of low grade and with good prognosis (Reviewed
in [9]). Zieger et al found that tumors with concomitant
CIS were generally FGFR3 wild type [10]. Classification of
the tumors using the previously reported CIS classifier [6]
showed a strong correlation between tumors classified as
"no CIS" and tumors with FGFR3 mutations. The results
indicate that the decreasing frequency of FGFR3 muta-
tions in patients with higher tumors stages is caused by
the emergence of tumors following a different molecular
pathway with no FGFR3 mutations but with presence of
CIS.
Previously, molecular classifier approaches for bladder
cancer have focused on delineation of best markers. The
use of whole pathways for classification has to our knowl-
edge not been investigated. Here, we developed a pathway
based classifier approach to predict presence or absence of
CIS in patients suffering from non muscle invasive blad-
der cancer. This is an explorative approach based on the
assumption that genes, which, at an individual level, con-
tribute minimally can have explanatory effects when their
effects are evaluated together. We computed the pairwise
correlations between the expression of transcription fac-
tors (TFs) in 37 signalling pathways. From pathways
where TFs behaved coherently we used the expression of
the TFs to predict presence or absence of concomitant CIS.
Methods
Datasets
Three datasets previously described were included in the
analysis: 1) A papillary tumor set consisting of material
from 28 patients with non muscle invasive bladder
tumors: 15 samples from patients with Ta tumors without
CIS in selected site biopsies at any visit and 13 patients
with Ta or T1 tumors with concomitant CIS. All patients
had no history of muscle invasive tumors [6]. The clinical
data for these patients is listed in Additional File 1. 2) 9
histologically normal urothelial samples from individuals
with prostatic hyperplasia or urinary incontinence and 10
biopsies from 5 cystectomy specimens. Five of the 10
biopsies were CIS lesions and five were histological nor-
mal samples located adjacent to CIS. The latter were pre-
viously shown to express the CIS signature [6]. 3) Further,
data from twenty-three patients suffering from T2-4 mus-
cle invasive bladder tumors were also included. For
description of these data, see [11]. All original data are
found at [12] with accession numbers GSE3167 and
GSE5287.
Informed consent was obtained from all enrolled patients
and the protocol was approved by the Scientific Ethical
Committee of Aarhus County.
Gene expression was measured using Affymetrix HG-
U133A GeneChips with 22,283 probes covering 14,500
genes. Gene expression measures were generated and data
normalized using the GCRMA method [13] in ArrayAssist
(4.2.0, Stratagene). Hierarchical cluster analysis was con-
ducted using Gene Cluster 2.0 [14] and TreeView 2.0 wasBMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
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used for visualization [15]. The Principal Component
Analysis (PCA) was carried out using the PCA function in
R.
Canonical pathways and transcription factors
All canonical signalling pathways in Ingenuity Pathway
Analysis (IPA) were analysed to identify if they contained
transcriptional regulators. These 43 pathways contained
188 transcriptional regulators and the regulators were
studied on the Ingenuity's "Gene View Pages" to ensure
that they contained a classical DNA binding domain (zinc
finger domains, homeodomain or homeoboxes, helix-
loop-helix domains, winged-helix (forkhead) proteins, or
leucine-zipper proteins). 116 (62%) TFs had a DNA bind-
ing domain and were enrolled for further analysis.
For each pathway a list of TFs was composed, and genes
were mapped by Ingenuity using Entrez Gene IDs.
Transcription factors and downstream targets
The transcription factor's (TF's) downstream targets were
identified in Ingenuity by adding the TF to "my pathway
page". Using the database all node types, which were
linked directly and downstream to the TF through the
search-words "activation", "inhibition", "expression", or
"transcription", were defined as downstream targets. Lists
of the extracted downstream targets were exported with
Entrez Gene identifiers. We identified 348 unique down-
stream targets for the 12 TF's in the 4 significant differen-
tially regulated pathways. After filtering the data the
analysis included 219 unique downstream targets.
Probes, filtering of data, and linking to Entrez Gene 
Identifiers
Non-unique probes with "_x_at" suffix were excluded.
The annotation of probes to genes was based on annota-
tion files from NETAFFX Analysis Center (downloaded 17
August 2006). Due to Unigene Id being less ambiguous
than EntrezGene Id, we used Unigene Id for the identifi-
cation of genes. If a gene contained both "_s_at" and "_at"
probes the last were preferred. If more than one probe cor-
responded to the same UniGene ID the mean expression
value was calculated. The outcome was a list of 12,356
genes of which 8,943 were covered by "_at" probes.
To exclude non-varying and non-expressed genes the data
were filtered to include only genes where at least 2 sam-
ples had a log2-expression above 6, giving 5,562 genes or
~45% of the whole dataset. 59 of the selected 116 TFs ful-
filled the filtering criteria. Entrez gene Ids were mapped to
UniGene numbers for the 116 selected TFs to link the
expression values to the pathways. The 59 TFs and corre-
sponding gene expression data are listed in Additional File
2.
Scores
Pearson correlations were calculated to determine the cor-
relation between a pair of genes g and h for all samples s:
where xgs denotes the expression value for gene g in sam-
ples s and   is the mean of expression values for gene g.
As in Breslin et al. [16] we defined the Group Correlation
Score (GCS) as the sum of squares of Pearson correlations.
Squaring ensured that both positive and negative correla-
tions contributed to the score.
We computed Pearson correlations for all pairs of TFs in a
pathway and defined Transcription Factor Group Correlation
Score (TF.GCS) as the sum of squares of these correlations.
Further, we calculated the correlations between the down-
stream targets of a specific transcription factor and defined
the Downstream Target Group Correlation Score (DT.GCS) as
the sum of squares of these correlations.
Permutations and p-values
For each score an equal number of genes were randomly
selected and the GCS computed. This was repeated 10,000
times. The significance of the true GCS was determined as
the number of permutations having a score higher than
the true score, e.g. if 1 out of the 10,000 permutations had
a GCS higher than the GCS calculated from the expression
values from TFs in a specific pathway the p-value would
be 0.0001.
Leave-One-Out Cross-validations
We used the expression level of TFs from pathways where
the TFs correlated coherently to predict presence or
absence of CIS. We used a maximum likelihood Leave-
One-Out Cross-Validation (LOOCV) classifier approach
as previously described [7]. LOOCV was conducted using
1) the TFs for each pathway and 2) using all TFs found in
significant pathways together. No selection of best per-
forming genes was applied Fisher's Exact test was used to
test whether the predictions were significantly different
from the pathological diagnoses of CIS.
Results
Co-expression of transcription factors in signalling 
pathways
First we aimed at identifying active signalling pathways
based on the expression level of transcriptional regulators.
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Therefore, our first issue was to identify pathways where
the TFs behaved coherently at the transcriptional level,
indicating that the whole pathway was affected. We used
the canonical signalling pathways included in IPA and
defined the Transcription Factor Group Correlation Score
(TF.GCS) based on Pearson correlations calculated from
expression values of the TFs in the canonical pathways. A
high score implies a coherent expression. Clinical infor-
mation was not included to calculate the score.
We calculated TF.GCS for 37 pathways and based on
10,000 random permutations of the 12,356 genes we
computed an associated p-value. p-values were not avail-
able from six pathways due to presence of only one TF (see
Additional File 3). Four of thirty-seven signalling path-
ways from IPA showed a p-value < 0.05: FGF signalling
pathway (3 TFs), p-value = 0.0021; p38 MAPK signalling
(9 TFs), p-value = 0.0021; cAMP signalling pathway (2
TFs), p-value 0.0099; Calcium signalling (5 TFs), p-value
= 0.0318 (Table 1). None of the four pathways were sig-
nificant after Bonferroni correction, however, the 37 avail-
able p-values were clearly non-uniformly distributed and
showed an overweight of low p-values (mean 0.388; p <
0.005; see Additional File 4), indicating that some of the
TF.GCSs are non-random.
For these four pathways (with 12 TFs), we also calculated
a Group Correlation Score between the downstream tar-
gets (DTs) of the single TFs. Nine of the 12 TFs had more
than one downstream target and for these TFs DT.GCS
was computed based on the expression levels of the DTs.
p-values were obtained by permutation tests using 10,000
random permutations (see Additional File 5). Only one
TF demonstrated a significant correlation between the
downstream targets: STAT1 (17 DTs): p-value < 0.0001.
Classification of tumors based on pathways with 
coherently expressed transctiption factors
After identifying four pathways with correlated expression
between TFs, we investigated if the expression level of
these coherently expressed TFs could be used to classify
the tumor samples according to CIS diagnoses of the
patients. We used a maximum likelihood classifier as pre-
viously described [7] to perform Leave-One-Out Cross-
Validation (LOOCV) based on both the TFs in each indi-
vidual pathway and on all 12 TFs. The expression levels of
the 12 TFs are listed in Additional File 6. For three of the
four pathways we were able to classify the samples accord-
ing to CIS status significantly: Calcium signalling (Fisher's
Exact Test, p = 0.02); FGF signalling (Fisher's Exact Test, p
= 0.0004); and p38 MAPK signalling (Fisher's Exact Test,
p = 0.0056). Furthermore, all twelve TFs from the four
pathways showed classification significantly associated
with CIS status (Fisher's Exact Test, p = 0.02). See Addi-
tional File 7.
Gene expression in the FGF and p38 MAPK pathways in 
CIS versus no-CIS associated tumors
We found that the ability to predict CIS status based on
the TFs in the P38 MAPK pathway (Figure 1) was most
interesting since it contained a relative large number of
TFs. Further, it has previously been suggested to have a
role in bladder cancer development [9]. Moreover, the
FGF pathway (Figure 2) was also interesting because it,
among other genes, contained the well described FGF
receptor, FGFR3. We calculated the mean log ratios of all
expressed genes from the tumors with concomitant CIS
compared to the expression in tumors without concomi-
tant CIS and superimposed the gene expression data to
the FGF and p38/MAPK canonical pathways. The canoni-
cal pathway for p38 MAPK signalling showed that the
majority of genes were up regulated in tumors with adja-
cent CIS compared to tumors without adjacent CIS (Fig-
ure 1). For example interleukine 1 (IL-1), which activates
the pathway, was found to be up regulated together with
its receptor, interleukin 1 receptor beta (IL1R). Further,
the kinases mitogen activated kinase kinase kinases,
MAP3K5 and MAP3K7 were both up regulated like the
kinase-kinase MAP2K4 and the mitogen activated kinase
p38 MAPK α. In the nucleus, p38 MAPK α regulates tran-
scription of several targets, and our data showed that in
tumors with concomitant CIS the majority of these targets
were up regulated, like cAMP responsive element binding
protein 1 (CREB1), activating transcription factor 1 and 2
(ATF1, ATF2), MADS box transcription enhancer factor 2,
polypeptide A and C (MEF2A, MEF2C), signal transducer
and activator of transcription 1 (STAT1), while DNA-dam-
age-inducible transcript 3 (DDIT3 = CHOP) was down
regulated.
The canonical pathway for FGF signalling showed like-
wise an up regulation of the majority of the genes includ-
Table 1: Pathways with significant transcription factor correlations (TF.GCS).
Pathway Transcription factors in pathways p-value of TF.GCS
FGF signalling CREB1, ATF2, STAT3 0.0021
P38 MAPK signalling CREB1, ATF2, DDIT3, HMGN1, MEF2A, MEF2C, MYC, ATF1, STAT1 0.0021
cAMP signaling CREB1, STAT3 0.0099
Calcium Signaling CREB1, CREBBP, MEF2A, MEF2C, HDAC3 0.0318BMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
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p38 MAPK canonical signalling pathway Figure 1
p38 MAPK canonical signalling pathway. Genes are colored according to the log ratio gene expression values between tumors 
with concomitant CIS and tumors without concomitant CIS. Yellow gene-symbols indicate up-regulation and blue gene sym-
bols indicate down-regulation. The pathway is from the Ingenuity software.BMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
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ing some of the kinases from the MAPK signalling like
MAPK1, MAP2K1 and MAP3K5. Likewise, signal trans-
ducer and activator of transcription 3 (STAT3) and p38
MAPK (MAPK14) were up regulated while FGFR3 was
down regulated in tumors with concomitant CIS com-
pared to tumors without concomitant CIS (See Figure 2).
PCA and hierarchical cluster analysis
Since the P38 MAPK pathway contained most of the 12
TFs we continued our analysis focusing on this pathway.
To visualize the expression of the different TFs in this
pathway a PCA was made and a biplot constructed. On
the biplot, colors were superimposed to show the two
groups of tumors (tumors with or without concomitant
CIS). The biplot shows the first two principal components
from the PCA of the p38 MAPK signalling pathway (Figure
3).
The first principal component (x axis) explains 48% of the
variation and is positively correlated with DDIT3, uncor-
related with MYC and negatively correlated with the main
group of genes, i.e. all other genes. The second principal
component (y axis) explains 13% of the variation and is
FGF canonical signalling pathway Figure 2
FGF canonical signalling pathway. Genes are colored according to the log ratio gene expression values between tumors with 
concomitant CIS and tumors without concomitant CIS. Yellow gene-symbols indicate up-regulation and blue gene symbols 
indicate down-regulation. The pathway is from the Ingenuity software.BMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
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negatively correlated with MYC and not highly correlated
with the other genes.
Patients located on the left of the plot have a low first prin-
cipal component, and hence a high expression for the
main group of genes and a negative expression for DDIT3,
whereas the opposite is the case for patients located on the
right of the plot. Patients 1182 and 763 is located on the
upper part of the plot and therefore have a high value of
the second principal component, i.e. a low expression of
MYC.
By superimposing colours on the plot we show that
tumors with concomitant CIS are located on the left of the
plot, and therefore have the main group of genes up regu-
lated and DDIT3 down regulated. The plot indicates that
the two tumors with concomitant CIS from patients 1182
and 763 may be a separate group with MYC down regu-
lated.
The PCA biplot for the p38 MAPK pathway also visualises
that expression for most of the genes apart from MYC and
DDIT3 is positively correlated, while being negatively cor-
related with DDIT3. MYC is nearly uncorrelated with all
other genes in the pathway.
To analyze this further, we conducted a cluster analysis of
the gene expression of the twelve TFs from the four path-
ways (see Figure 4). One cluster branch contained mainly
down regulated genes. Here we found 3 CIS patients and
Biplot of the first two principal components from the Principal component analysis of the p38 MAPK signalling pathway Figure 3
Biplot of the first two principal components from the Principal component analysis of the p38 MAPK signalling pathway. 
Tumors with concomitant CIS are indicated with red numbers. Tumors with no concomitant CIS are indicated with blue num-
bers.
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11 no CIS patient. The second cluster branch contained 10
patients with CIS and four without CIS (Fisher's Exact test,
p-value = 0.0213).
Pathway regulation in muscle invasive tumors
We next investigated whether the pathway regulations
identified in the tumors with concomitant CIS were com-
parable to the pathway regulations identified in patients
with muscle invasive bladder tumors. Figure 5 shows the
expression of the twelve TFs in tumors with and without
concomitant CIS and in muscle-invasive tumours (23
patients). The expression of seven of the twelve genes was
significantly different when comparing the non muscle
invasive tumors without concomitant CIS to both the
tumor with concomitant CIS and to the muscle invasive
tumors (t-test, ATF2, p-value = 1.2E-4; CREBBP, p-value =
1.2E-2; MEF2A, p-value = 1.7E-4; MEF2C, p-value = 1.7E-
3;  ATF1, p-value = 2.6E-2; STAT1, p-value = 1.3E-4;
STAT3, p-value = 1.2E-2). A hierarchical cluster analysis
based on the seven genes significantly separated the
patients according to the groups no CIS and CIS/Invasive
(χ2-test, p < 2.0E-5). This result indicated that the tumors
with concomitant CIS showed an expression similar to the
expression found in muscle invasive tumors for the major-
ity of the twelve selected TFs. This is comparable to the
large similarities previously found [6].
Cluster analysis of 28 bladder cancer patients (columns) based on the gene expression of the twelve transcription factors  found in the four pathways with significantly correlating transcription factors (rows) Figure 4
Cluster analysis of 28 bladder cancer patients (columns) based on the gene expression of the twelve transcription factors 
found in the four pathways with significantly correlating transcription factors (rows). Up regulated genes from tumors without 
concomitant CIS to tumors with concomitant CIS are coloured yellow while down regulated genes are blue. The colour bar 
indicates the clinical diagnosis, green, concomitant CIS; orange, no concomitant CIS.BMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
Page 9 of 13
(page number not for citation purposes)
Pathway based classification using normal and CIS 
samples
After identification of pathways with relevance for identi-
fication of concomitant CIS in non muscle invasive blad-
der carcinomas we investigated if these pathways were
also important in actual CIS lesions. For this we used a set
of nine urothelial samples from healthy individuals and
ten biopsies from cystectomy specimens (five were CIS
lesions and five were histological normal samples located
adjacent to CIS). The five histologically normal samples
located adjacent to CIS were previously shown to express
the CIS signature [6] and this set was previously used to
validate the CIS classifier developed by Dyrskjøt et al. [6]
We used a hierarchical cluster analysis approach for clas-
sification of the samples (see Additional File 8). The p38
MAPK signalling pathway showed a significant correla-
tion to CIS status for the patients in these independent test
samples (p = 0.0198), while the other pathways showed
no significant correlation to CIS status in this small sam-
ple set. The TFs from the four pathways combined did not
show a statistically significant correlation to CIS status,
although the p-value was borderline (p = 0.0698; Figure
6). Like in the papillary tumors, the cluster analysis
showed that the expression of the majority of the twelve
genes was down regulated in normal biopsies compared
to the ten biopsies from cystectomy specimens. The biop-
sies from the cystectomy specimens clustered together,
and this was independent of whether the specimen was a
CIS lesion or a histological normal sample located adja-
cent to CIS, underscoring the tight relation between CIS-
and "normal" looking biopsies in this urothelium. DDIT3
was up-regulated in the normal samples compared to the
biopsies from cystectomy specimens, while MYC was up
regulated in the cystectomy specimens but not differen-
tially expressed in the papillary tumors.
Discussion
Several studies have focused on construction of microar-
ray based classifiers for prediction of various aspects of
bladder cancer like stage [7,8,11,17,18], progression
[7,8,19], recurrence [7], survival [18,20], and treatment
response [21]. These classifiers consist of up till a few hun-
dred genes, which not necessarily are associated with the
same molecular pathways. Many of these lists have been
validated in independent test sets but little overlap has
been observed between classifiers identified by different
groups, addressing the same issue. Our study differs from
the traditional classifier approach since we were interested
in identifying whole pathways, which are associated with
a distinct disease course. A comprehensive understanding
of the underlying molecular networks involved in disease
development and progression is necessary for develop-
ment of new treatments and may also be useful in a
molecular diagnostic approach as a supplement to the
common pathological classification.
Here, we used a pathway based classifier approach to pre-
dict a clinical parameter in patients suffering from non
muscle invasive bladder cancer. We used IPA in a hypoth-
esis generative manner to suggest which pathways are
most relevant for detection of concomitant CIS. IPA is a
relatively new bioinformatics tool, which enables the user
to get information of relationships between genes of inter-
est and about functions, diseases, and drugs, related to
Heatmap illustrating the expression level of the twelve transcription factors (rows) found in the four signalling pathways: FGF,  p38 MAPK, cAMP and calcium Figure 5
Heatmap illustrating the expression level of the twelve transcription factors (rows) found in the four signalling pathways: FGF, 
p38 MAPK, cAMP and calcium. The columns contain expression of the 15 patients without CIS, 13 patients with adjacent CIS 
and 23 patients with muscle invasive bladder carcinoma, mTCC. Up regulated genes are yellow, down regulated genes are blue, 
while black indicates no change with no CIS samples as reference. The colour bar indicates the clinical diagnosis, green, CIS; 
orange, no CIS, gray, muscle invasive tumors.BMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
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Cluster analysis of 9 normal samples and 10 samples from cystectomies with CIS Figure 6
Cluster analysis of 9 normal samples and 10 samples from cystectomies with CIS. Top: TFs from p38 MAPK signalling pathway. 
Bottom: All 12 TFs used for clustering. The color bar indicates the clinical diagnosis, blue, histologically normal urothelial sam-
ples; pink, cystectomy specimens.BMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
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these genes. IPA contains lists of metabolic and signalling
pathways. These pathways are termed canonical path-
ways, since they contain well-established knowledge
about specific relationships between groups of genes. The
challenge related to the use of these networks is that it is
arbitrary to define where a network starts and ends. More-
over, it should be noted that the information in the IPA
knowledge base is gathered from a broad variety of condi-
tions and from three different organisms (human, mouse,
and rat). Further, regulation is affected on several levels:
the transcriptional level and the post-transcriptional level,
where phosphorylations, glucosylations and various other
epigenetic events contribute.
The advantage of a network based strategy is that path-
ways can include small contributions from single genes.
Alone these genes might not seem to have an effect and
would not have been detected in a single-gene analysis
strategy. Together, these small contributions may have a
great impact on the malignant development. The impor-
tance of an orchestrated effect has previously been shown
in a excellent study of breast cancer [22]. Further, using
such an additive strategy implies that the risk of false pos-
itives may be minimized since effects of single genes must
be in consensus with the effects from other genes in the
pathway before they will be ascribed any importance.
We investigated the pairwise correlations between TFs in
37 signalling pathways from IPA and calculated the sum
of squared correlations across samples in a set of twenty-
eight non muscle invasive bladder carcinomas. We identi-
fied four signalling pathways (p38 MAPK, FGF, calcium
and cAMP containing twelve TFs in total) where the
expression of TFs seemed to behave coherently. TF expres-
sion levels in three of these pathways (FGF, p38 MAPK,
and calcium signalling) or the expression of the twelve TFs
together could be used to predict presence or absence of
concomitant CIS. Comparing the non muscle invasive
samples with twenty-three patients suffering from muscle-
invasive bladder carcinoma showed that the majority of
the TFs' expression in non muscle invasive samples with-
out concomitant CIS was significantly different from the
expression in non muscle invasive tumors with adjacent
CIS and in muscle invasive tumors. This is consistent with
previous results indicating that CIS is the precursor for
invasive disease [3]
Our study indicates that the expression of genes involved
in p38 MAPK signalling pathway is up regulated in tumors
with concomitant CIS. p38 is a mitogen activated protein
kinase (MAPK) and is part of one of three distinct MAPK
pathways, which also include the ERK1 and 2 pathways
and the JNK1 pathway. These pathways are signalling cas-
cades involving at least three levels of MAP kinases. The
p38 MAPKs respond to environmental stress like ultravio-
let light, heat, osmotic shock, and inflammatory
cytokines. The signal activates the serine/threonine
kinases termed MAPKKK, which phosphorylate the MAPK
kinases (MAPKK). The MAPKKs then activate the p38
MAPK kinases by dual phosphorylation of specific threo-
nine and tyrosine residues. Activated p38 MAPK can phos-
phorylate several substrates like TFs, other kinases and
cytosolic proteins. Some of these components are respon-
sible for inflammatory cytokine production and a great
effort has been done to try to develop inhibitors of p38
MAPK to prevent inflammatory diseases like rheumatoid
arthritis [23].
Mutations of the FGF receptor 3 gene (FGFR3) have been
shown to be a distinct characteristic of tumors with low
grade and stage. Up to 80% of low-grade Ta tumors show
the mutations, which constitutively activate the receptor.
It has been suggested that the consequences of FGFR3 acti-
vation in the urothelium is activation of the MAPK and/or
the PI3-kinase pathway [9,24]. Our results highlight the
already known relation between the FGF and the p38
MAPK pathways. The FGF pathway contains members of
the mitogen-activated protein kinase family like MAP2K3,
MAP2K6, MAP3K5, MAPK14, MAPKAPK2, and p38
MAPK (See Figure 1 and Figure 2). Constitutive activation
of FGFR3 will probably cause constitutive activation of
p38 MAPK and thereby activate the entire p38 MAPK sig-
nalling pathway. Interestingly, in the papillary tumors we
found that the expression level of TFs from the FGF path-
way could be used to predict presence or absence of con-
comitant CIS. However, the FGF pathway does not seem
to play such a clear role in the CIS lesions themselves, as
these could not be identified based on FGF expression
alone. Whether this is due to cells being lost by exfolia-
tion, so we do not measure the right cells, or a regulatory
process is overruling the FGF signalling in the CIS lesions,
which among other parameters are surrounded by mas-
sive inflammation, is at present unknown.
In a study conducted by Breslin et al. [16] a pathway
approach was used on datasets from breast cancer [25,26]
and leukemia [27]. In that study expression values of
downstream targets were included. We tried to include
downstream targets in our analysis and identified down-
stream targets for the 12 TFs using direct downstream rela-
tions known by the Ingenuity Pathway Knowledge Base
(IPKB). However, only one of nine TF showed a signifi-
cant GCS for the downstream targets. We believe that the
information gathered in the IPKB is too unspecific to
identify downstream targets in an automatic manner.
Identification of TF binding motifs followed by bioinfor-
matics screenings of possible binding sites would be nec-
essary to predict downstream targets more accurately.BMC Cancer 2008, 8:37 http://www.biomedcentral.com/1471-2407/8/37
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Conclusion
In conclusion, we have shown that twelve TFs from four
signalling pathways can be used to predict presence of
concomitant CIS and especially TFs from the p38 MAPK
signalling pathway seem to be important. Other pathways
may be of importance but could not be delineated in this
relative limited sample set. The approach is convincing as
it shows how complex multiparameter data sets can be
subjected to bioinformatic analyses and pin-point path-
ways that may later be targets for therapeutic intervention.
Furthermore, it would be interesting to use a similar strat-
egy to investigate the pathways involved in invasive and
metastatic disease courses.
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